Modeling of human tumor xenografts and dose rationale in oncology.

Xenograft models are commonly used in oncology drug development. Although there are discussions about their ability to generate meaningful data for the translation from animal to humans, it appears that better data quality and better design of the preclinical experiments, together with appropriate data analysis approaches could make these data more informative for clinical development. An approach based on mathematical modeling is necessary to derive experiment-independent parameters which can be linked with clinically relevant endpoints. Moreover, the inclusion of biomarkers as predictors of efficacy is a key step towards a more general mechanism-based strategy.

[1]  Shinji Yamazaki,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models , 2008, Drug Metabolism and Disposition.

[2]  Benoît You,et al.  A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. , 2011, European journal of cancer.

[3]  O. Pasqua.  PKPD and Disease Modeling: Concepts and Applications to Oncology , 2011 .

[4]  G. Bonadonna,et al.  Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Efthymios Manolis,et al.  New pathway for qualification of novel methodologies in the European medicines agency , 2011, Proteomics. Clinical applications.

[6]  L. Norton,et al.  The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens , 2006, Nature Clinical Practice Oncology.

[7]  Giuseppe De Nicolao,et al.  A Minimal Model of Tumor Growth Inhibition , 2008, IEEE Transactions on Biomedical Engineering.

[8]  Giuseppe De Nicolao,et al.  In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time , 2003, Cancer Chemotherapy and Pharmacology.

[9]  Peter L. Bonate,et al.  Modeling Tumor Growth in Oncology , 2011 .

[10]  Laird Ak.  Dynamics of Tumour Growth , 1964 .

[11]  G. De Nicolao,et al.  A model-based approach to the in vitro evaluation of anticancer activity , 2009, Cancer Chemotherapy and Pharmacology.

[12]  H. Byrne.  Dissecting cancer through mathematics: from the cell to the animal model , 2010, Nature Reviews Cancer.

[13]  Karlyne M. Reilly,et al.  Genetically engineered mouse models in cancer research. , 2010, Advances in cancer research.

[14]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Au,et al.  A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect , 2000, Cancer Chemotherapy and Pharmacology.

[16]  M Rocchetti,et al.  Predicting the active doses in humans from animal studies: a novel approach in oncology. , 2007, European journal of cancer.

[17]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[18]  David R. Jones,et al.  New regulatory framework for cancer drug development. , 2012, Drug discovery today.

[19]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[20]  Helen M Byrne,et al.  Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. , 2004, Journal of theoretical biology.

[21]  L. Preziosi,et al.  Modelling and mathematical problems related to tumor evolution and its interaction with the immune system , 2000 .

[22]  J. Rygaard,et al.  Heterotransplantation of a human malignant tumour to "Nude" mice. , 2009, Acta pathologica et microbiologica Scandinavica.

[23]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[24]  S. Schnell,et al.  A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies , 2006, Theoretical Biology and Medical Modelling.

[25]  Iñaki F Trocóniz,et al.  Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. , 2008, European journal of cancer.

[26]  Antje Walz,et al.  Modeling of tumor growth and anticancer effects of combination therapy , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  H. H. Lloyd,et al.  Kinetic parameters and growth curves for experimental tumor systems. , 1970, Cancer chemotherapy reports.

[28]  L. Kèlland,et al.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. , 2004, European journal of cancer.

[29]  M Rocchetti,et al.  A mathematical model to study the effects of drugs administration on tumor growth dynamics. , 2006, Mathematical biosciences.

[30]  D. Hicklin,et al.  Human Tumor Xenograft Efficacy Models , 2011 .

[31]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[32]  M. Volm,et al.  Human tumor xenografts as model for drug testing , 1988, Cancer and Metastasis Reviews.

[33]  Evelyn D. Lobo,et al.  Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.

[34]  Zhihui Wang,et al.  Multiscale agent-based cancer modeling , 2009, Journal of mathematical biology.

[35]  Deepak Sampath,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941 , 2010, Drug Metabolism and Disposition.

[36]  B Ribba,et al.  A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. , 2006, Journal of theoretical biology.

[37]  Jong Hwan Sung,et al.  A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. , 2009, Journal of pharmaceutical sciences.

[38]  M. Hollingshead,et al.  Antitumor efficacy testing in rodents. , 2008, Journal of the National Cancer Institute.

[39]  Donald E. Mager,et al.  Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems , 2010, The AAPS Journal.

[40]  S. Jonathan Chapman,et al.  Mathematical Models of Avascular Tumor Growth , 2007, SIAM Rev..

[41]  G. De Nicolao,et al.  Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. , 2009, European journal of cancer.

[42]  H. Frieboes,et al.  Nonlinear modelling of cancer: bridging the gap between cells and tumours , 2010, Nonlinearity.

[43]  Laird Ak.  DYNAMICS OF TUMOR GROWTH. , 1964 .

[44]  Thomas J Lynch,et al.  The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Jelena Pjesivac-Grbovic,et al.  A multiscale model for avascular tumor growth. , 2005, Biophysical journal.

[46]  P. Vrignaud,et al.  Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice , 1996, Anti-cancer drugs.

[47]  B P Booth,et al.  Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[48]  G. De Nicolao,et al.  A pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development. , 2005, Basic & clinical pharmacology & toxicology.

[49]  Jan Fagerberg,et al.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Deisboeck,et al.  Simulating non-small cell lung cancer with a multiscale agent-based model , 2007, Theoretical Biology and Medical Modelling.

[51]  M. Wientjes,et al.  Design and analysis of in vitro antitumor pharmacodynamic studies. , 1995, Cancer research.

[52]  G. Nicolao,et al.  Population modeling of tumor growth inhibition in vivo: application to anticancer drug development , 2004 .

[53]  L. Norton,et al.  Growth curve of an experimental solid tumor following radiotherapy. , 1977, Journal of the National Cancer Institute.

[54]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.

[55]  J. T. Kemper,et al.  Modeling biomarker dynamics with implications for the treatment of prostate cancer , 2007 .

[56]  M. Sliwkowski,et al.  Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[57]  Z. Bajzer,et al.  Conceptual frameworks for mathematical modeling of tumor growth dynamics , 1996 .

[58]  S. Salmon,et al.  Kinetics of tumor growth and regression in IgG multiple myeloma. , 1972, The Journal of clinical investigation.

[59]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Paolo Ubezio,et al.  A Generalised Age- and Phase-Structured Model of Human Tumour Cell Populations Both Unperturbed and Exposed to a Range of Cancer Therapies , 2007, Bulletin of mathematical biology.

[61]  Gary K. Schwartz,et al.  Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents , 2010, Cancer Chemotherapy and Pharmacology.

[62]  D. Ouellet.  Benefit–risk assessment: the use of clinical utility index , 2010, Expert opinion on drug safety.

[63]  G. Nicolao,et al.  Re: Antitumor Efficacy Testing in Rodents. Author's reply , 2009 .